Methods and Results: To compare prevention by cilostazol
and aspirin of progression of atherosclerosis, we conducteda prospective, randomized, open, blinded end point study in 4 East Asian countries.
After the baseline data collection cilostazol
was given to the group A while the group B didn't receive cilostazol
Remnant lipoprotein particles induce apoptosis in endothelial cells by NAD(P)H oxidase-mediated production of superoxide and cytokines via lecitin-like oxidized low-density lipoprotein receptor-1 activation: prevention by cilostazol
Potentially, drugs designed to relax and dilate the walls of blood vessels, such as cilostazol
(Pletal), may be recommended to ease the pain of walking.
Sutariya, "Preparation and characterization of microemulsion of cilostazol
for enhancement of oral bioavailability," Current Drug Delivery, vol.
20 Takayuki Matsumoto, Tsuneo Kobayashi, Kentaro Wakabayashi and Katsuo Kamata; Cilostazol
improves endothelium-de- rived hyperpolarizing factor-type relaxation in mesenteric arteries from diabetic rats, Am J Physiol Heart CircPhys- io,2005;H1933-H1940
(PLETAL): is an antiplatelet drug with vasodilatation properties; it is approved for use in intermittent claudication where there is no pain at rest and no tissue necrosis.
Population pharmacokinetic analysis of cilostazol
in healthy subjects with genetic polymorphisms of CYP3A5, CYP2C19 and ABCB1.
4) So have cilostazol
(5) and naftidrofuryl, (6) as well as lipid-lowering agents.
There have also been reports about improvement of apathy and cognitive function after stroke by treatment with cilostazol
18] 5 [micron]m; 4,6 x 250 mm LC-MS/MS ELL/ 250 [micron]L Atlantis (ESI modo Cilostazol
If you have severe pain or cramping in your legs when you walk, your health care professional may recommend clopidogrel (Plavix), cilostazol
(Pletal) or pentoxifylline (Trental).
The only two drugs currently approved in the United States for this indication, pentoxifylline and cilostazol
, are reported to increase walking distance by 15% and 25%, respectively.
Their topics include cilostazol
and dipyridamole: much more than weak inhibition of platelets, unfractionated heparin and low molecular weight heparin in ischemic heart disease, vitamin K antagonists, anti-thrombotic strategies in patients undergoing elective percutaneous coronary interventions, and anti-thrombotic therapy in venous thrombosis and pulmonary embolism.
This effect of cilostazol
was not seen in non-carriers of the loss-of-function polymorphism.